Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity

Blood Advances

Volumn 2, Issue 7, 2018, Pages 745-753

  DeFilipp, Zachariah ^a   Peled, Jonathan U ^b,c   Li, Shuli ^d   Mahabamunuge, Jasmin ^a   Dagher, Zeina ^a   Slingerland, Ann E ^b,c   Del Rio, Candice ^a   Valles, Betsy ^a   Kempner, Maria E ^a   Smith, Melissa ^a   Brown, Jami ^a   Dey, Bimalangshu R ^a   El Jawahri, Areej ^a   McAfee, Steven L ^a   Spitzer, Thomas R ^a   Ballen, Karen K ^e   Sung, Anthony D ^f   Dalton, Tara E ^f   Messina, Julia A ^f   Dettmer, Katja ^g   Liebisch, Gerhard ^h   Oefner, Peter ^g   Taur, Ying ^b,c   Pamer, Eric G ^b,c   Holler, Ernst ^h   Mansour, Michael K ^a   Van Den Brink, Marcel R M ^b,c   Hohmann, Elizabeth ^a   Jenq, Robert R ⁱ   Chen, Yi Bin ^a   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF REGENSBURG   (Germany)

^h UNIVERSITY HOSPITAL REGENSBURG   (Germany)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYCLOPROPYL 5 [1 (2 FLUORO 3 PYRIDINYL) 5 METHYL 1H 1,2,3 TRIAZOL 4 YL] 2,3 DIHYDRO 1H ISOINDOL 1 ONE; ANTIBIOTIC AGENT; FLUDARABINE; INDICAN; MELPHALAN; METHOTREXATE; RAPAMYCIN; TACROLIMUS;

ABDOMINAL PAIN; ACUTE GASTROENTERITIS; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE MYELOID LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTEREMIA; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; DEATH; DRUG CAPSULE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENGRAFTMENT; FECAL MICROBIOTA TRANSPLANTATION; FECES COMPOSITION; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; INTESTINE FLORA; MALE; MICROBIAL DIVERSITY; MULTIPLE ORGAN FAILURE; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; OPEN STUDY; OVERALL SURVIVAL; PATIENT DECISION MAKING; PILOT STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN URINE LEVEL; RECOMMENDED DRUG DOSE; SEPSIS; SINGLE DRUG DOSE; STOOL DONOR; SURVIVOR; TREATMENT DURATION;

EID: 85048688282     PISSN: 24739529     EISSN: 24739537     Source Type: Journal    
DOI: 10.1182/bloodadvances.2018017731     Document Type: Article

References (36)

1. Peled JU, Hanash AM, Jenq RR. Role of the intestinal mucosa in acute gastrointestinal GVHD. Blood. 2016;128(20):2395-2402.
2. Staffas A, Burgos da Silva M, van den Brink MR. The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease. Blood. 2017;129(8):927-933.
3. Mathewson ND, Reddy P. The microbiome and graft versus host disease. Curr Stem Cell Rep. 2015;1(1):39-47
4. Taur Y, Jenq RR, Perales MA, et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood. 2014;124(7):1174-1182
5. Jenq RR, Taur Y, Devlin SM, et al. Intestinal blautia is associated with reduced death from graft-versus-host disease. Biol Blood Marrow Transplant. 2015; 21(8):1373-1383.
6. Peled JU, Devlin SM, Staffas A, et al. Intestinal microbiota and relapse after hematopoietic-cell transplantation. J Clin Oncol. 2017;35(15):1650-1659.
7. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108(4):500-508.
8. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-415.
9. Youngster I, Sauk J, Pindar C, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis. 2014;58(11):1515-1522.
10. Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312(17):1772-1778.
11. Youngster I, Mahabamunuge J, Systrom HK, et al. Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection. BMC Med. 2016;14(1):134.
12. Zhu W, Stevens AP, Dettmer K, et al. Quantitative profiling of tryptophan metabolites in serum, urine, and cell culture supernatants by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2011;401(10):3249-3261.
13. Weber D, Oefner PJ, Hiergeist A, et al. Low urinary indoxyl sulfate levels early after transplantation reflect a disrupted microbiome and are associated with poor outcome. Blood. 2015;126(14):1723-1728.
14. Taur Y, Xavier JB, Lipuma L, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012;55(7):905-914.
15. Rognes T, Flouri T, Nichols B, Quince C, Mahe F. VSEARCH: a versatile open source tool for metagenomics. PeerJ. 2016;4:e2584.
16. Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7(5):335-336.
17. Schloss PD, Westcott SL, Ryabin T, et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol. 2009;75(23):7537-7541.
18. Werner JJ, KorenO, Hugenholtz P, et al. Impact of training sets on classification of high-throughput bacterial 16s rRNA gene surveys. ISME J. 2012;6(1):94-103.
19. Wong RG, Wu JR, Gloor GB. Expanding the UniFrac Toolbox. PLoS One. 2016;11(9):e0161196.
20. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-381.
21. Weber D, Jenq RR, Peled JU, et al. Microbiota disruption induced by early use of broad-spectrum antibiotics is an independent risk factor of outcome after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(5):845-852.
22. Jenq RR, Ubeda C, Taur Y, et al. Regulation of intestinal inflammation bymicrobiota following allogeneic bonemarrow transplantation. JExpMed. 2012;209(5):903-911.
23. Golob JL, Pergam SA, Srinivasan S, et al. Stool microbiota at neutrophil recovery is predictive for severe acute graft vs host disease after hematopoietic cell transplantation. Clin Infect Dis. 2017;65(12):1984-1991.
24. Shono Y, van den Brink M. Empiric antibiotic use in allogeneic hematopoietic cell transplantation: should we avoid anaerobe coverage? Blood Adv. 2017; 1(25):2325-2328.
25. Andermann TM, Rezvani A, Bhatt AS. Microbiota manipulation with prebiotics and probiotics in patients undergoing stem cell transplantation. Curr Hematol Malig Rep. 2016;11(1):19-28.
26. Mathewson ND, Jenq R, Mathew AV, et al. Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat Immunol. 2016;17(5):505-513.
27. Waller EK, Giver CR, Rangaraju S, et al. Administation of a tryptophane metabolite, indole-3-carboxaldehyde, reduces graft versus host disease morbidity and mortality and enhances gastrointestinal barrier function in a murine model of allogeneic bone marrow transplantation. Blood. 2014;124:2420.
28. Liu F, Li P, Chen M, et al. Fructooligosaccharide (FOS) and galactooligosaccharide (GOS) increase bifidobacterium but reduce butyrate producing bacteria with adverse glycemic metabolism in healthy young population. Sci Rep. 2017;7(1):11789.
29. Ringden O, Remberger M, Holmberg K, et al. Many days at home during neutropenia after allogeneic hematopoietic stem cell transplantation correlates with low incidence of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2013;19(2):314-320.
30. Neemann K, Eichele DD, Smith PW, Bociek R, Akhtari M, Freifeld A. Fecal microbiota transplantation for fulminant Clostridium difficile infection in an allogeneic stem cell transplant patient. Transpl Infect Dis. 2012;14(6):E161-E165.
31. de Castro CG Jr, Ganc AJ, Ganc RL, Petrolli MS, Hamerschlack N. Fecal microbiota transplant after hematopoietic SCT: report of a successful case. Bone Marrow Transplant. 2015;50(1):145.
32. Mittal C, Miller N, Meighani A, Hart BR, John A, Ramesh M. Fecal microbiota transplant for recurrent Clostridium difficile infection after peripheral autologous stem cell transplant for diffuse large B-cell lymphoma. Bone Marrow Transplant. 2015;50(7):1010.
33. Falconer S, Moss E, Andermann T, et al. Fecal microbiota transplant is a potentially safe and effective treatment for Clostridium difficile infection in hematopoietic stem cell recipients. Biol Blood Marrow Transplant. 2016;22(3):S53-S54.
34. Bilinski J, Grzesiowski P, Sorensen N, et al. Fecal microbiota transplantation in patients with blood disorders inhibits gut colonization with antibioticresistant bacteria: results of a prospective, single-center study. Clin Infect Dis. 2017;65(3):364-370.
35. Kakihana K, Fujioka Y, Suda W, et al. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. Blood. 2016;128(16):2083-2088.
36. Spindelboeck W, Schulz E, Uhl B, et al. Repeated fecal microbiota transplantations attenuate diarrhea and lead to sustained changes in the fecal microbiota in acute, refractory gastrointestinal graft-versus-host-disease. Haematologica. 2017;102(5):e210-e213.